This Webinar aims to explore the latest developments in treating high risk AML patients with intensive chemotherapy: 1. To review the current treatment landscape in high risk AML and support the understanding of the prognosis for those patients diagnosed; 2. To educate the audience around the latest data for Vyxeos Liposomal in this patient population and best practice examples of how to manage patients from diagnosis through to treatment with therapies like Vyxeos Liposomal; 3. Panel discussion to answer audience questions and explore learnings; challenges and best practice during and outside of a pandemic; such as COVID-19.
Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.
